KEY TAKEAWAY: While there is talk of “patient engagement” and being more customer focused the failure of BMS’s drug, in a late stage clinical trial, is proof that pharma, above all else, is a business focused on the balance sheet.
KEY TAKEAWAY: While there is talk of “patient engagement” and being more customer focused the failure of BMS’s drug, in a late stage clinical trial, is proof that pharma, above all else, is a business focused on the balance sheet.